share_log

Piper Sandler Assumes AbCellera Biologics at Overweight, Announces Price Target of $20

Benzinga ·  Oct 13, 2023 06:29

Piper Sandler analyst Allison Bratzel assumes AbCellera Biologics (NASDAQ:ABCL) with a Overweight rating and announces Price Target of $20.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment